Genascence Announces Six-Month Results From Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
UF startup Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, announced positive interim safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001.
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology
UF startup Cannabix Technologies Inc., developer of marijuana and alcohol breath testing devices, has announced that it has made significant updates to its Cannabix Marijuana Breathalyzer technology to meet suggested emerging regulatory requirements in preparation for marketing.
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics, a clinical-stage gene therapy company specializing in genetic medicine to reverse or prevent blindness, has announced the initiation of Part B of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating the subretinal injection of ATSN-201 for treating XLRS.
Solid Biosciences Announces FDA IND Clearance for First-in-Industry Dual Route of Administration Gene Therapy To Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Solid Biosciences Inc., a biotechnology company that acquired UF startup AavantiBio, announced that the U.S. FDA has cleared its Investigational New Drug application for SGT-212 for the treatment of Friedreich’s ataxia.
Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials.
LightPath Technologies Begins Sustained Delivery of Infrared Assemblies to European Defense Customer
UF startup LightPath Technologies, Inc. announced that it has begun sustained delivery of infrared lens assemblies per the terms of the October 2024 Letter of Intent from a European defense customer for active duty use in first-person view (FPV) drone applications.
New Study Shows Shoplifting Is Up 93% Since Before the COVID-19 Pandemic
UF startup LPRC conducted a study to examine how theft and violence have evolved since before COVID-19. The study revealed a significant increase in both the average number of shoplifting incidents and the dollars lost due to shoplifting.
RTI Surgical Transforms Into Evergen, a Leading CDMO in Regenerative Medicine
UF startup RTI Surgical unveils its new corporate identity as Evergen, signaling its strategic evolution into a premier Contract Development and Manufacturing Organization (CDMO) providing biosolutions in regenerative medicine.
Portage Biotech Announces Letter of Intent With Immunova for an Option To Acquire iOx Therapeutics, Ltd
UF startup Immunova, LLC, a private Connecticut-based biotechnology company, has entered into a Letter of Intent with Portage Biotech, Inc. to advance its novel immuno-oncology therapies for cancer treatment.
Atsena Therapeutics Announces Dosing Completed in Part A of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
